Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (NASDAQ:IFRX) (the "Company"), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses.

The Company intends to use the net proceeds from the offering to advance its pipeline activities and for working capital and general corporate purposes.

The financing included participation from new and existing investors, including TCGX, a large healthcare-dedicated fund, Farallon Capital Management, Sirenia Capital Management LP, Columbia Threadneedle Investments, Great Point Partners, LLC, ADAR1 Capital Management, Coastlands Capital, Squadron Capital Management and other large new mutual funds, with participation from existing investors including a leading healthcare fund, 683 Capital, and others.

Guggenheim Securities acted as lead bookrunner for the offering. Oppenheimer & Co. and LifeSci Capital also acted as bookrunners for the offering. Raymond James and Needham & Company acted as co-lead managers for the offering. H.C. Wainwright & Co. and Lucid Capital Markets acted as co-managers for the offering.

A shelf registration statement relating to the ordinary shares sold in this offering was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on July 11, 2023. The offering was made only by means of a prospectus and prospectus supplement. The prospectus supplement and accompanying prospectus related to the ...